ArticleBreast cancer research and treatment2025
The association of contemporary mortgage lending bias and receipt of guideline-concordant systemic treatment among older women with breast cancer.
Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeStructural racism may be associated with disparities in breast cancer access to care and outcomes. We examined the association between contemporary mortgage lending bias (redlining) and the receipt of guideline-concordant systemic treatment.
methodsWomen with stage I-III invasive breast cancer in 2010-2017 were identified from the Surveillance, Epidemiology, and End Results-Medicare linked database. Contemporary redlining was estimated using 2010-2017 Home Mortgage Disclosure Act data. Simple and multiple logistic regression models estimated the unadjusted and adjusted odds of receiving guideline-concordant systemic treatment: appropriate receipt of chemotherapy, HER2/neu (HER2)-targeted therapy, hormonal therapy, and a composite systemic treatment measure.
resultsOverall compliance rates were 85%, 96%, and 87% for chemotherapy, HER2-targeted therapy, and hormonal therapy, respectively. For the composite outcome, 95% received some or fully concordant care. In unadjusted and adjusted models, women living in higher redlined neighborhoods were less likely to receive guideline-concordant care for all modalities, except hormonal therapy (p = 0.846). For HER2-targeted therapy and composite score, the redlining effect differed by dual Medicare-Medicaid enrollment eligibility status. Dual eligibility eliminated the negative effect of redlining. Among those not dual eligible, the negative effect of redlining persisted.
conclusionsOlder breast cancer survivors living in higher redlined areas were less likely to receive guideline-concordant chemotherapy, HER2-targeted therapy, and overall systemic treatment. While more work is needed to better understand structural racism and neighborhood socioeconomic disinvestment to address equitable access to cancer care, the housing sector may be one actionable policy target. Care teams should consider patient context to ensure high quality care.
Indexed as
Identifiers
41385117What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.